Developing national capability for the production and use of radiometal based radiopharmaceuticals
Loading...
Date
2013-04-11
Journal Title
Journal ISSN
Volume Title
Publisher
John Wiley & Sons, Inc
Abstract
Radiometals remain key radioisotopes for radio-medicine; the mainstay diagnostic medical imaging isotope, 99mTc, and important radioisotopes for radiotherapy, 90Y and 153Sm. However, the worldwide growth in PET centres, driven by the wildly successful [18F]-FDG, has provided a yet to be seized opportunity to deliver radiometal-based radiopharmaceuticals with clinical relevance to researchers. An ever growing set of radiometals is becoming available in Australia covering a wide range of half-lives, nuclear and chemical properties, these include 64Cu, 68Ga, 86Y, 89Zr, and looking into the near future, 44Sc, 45Ti and 90Nb.
ANSTO's Lifesciences division is working to provide the Australian academic and clinical communities access to the following key areas.
Radioisotope supply
Two in-house 68Ge/68Ga generators; one solely for research and a larger generator for pre-clinical trials, provide access to this key radioisotope. ANSTO has provided financial and technical support to numerous cyclotron centres around Australia for development of solid targetry facilities, ensuring supply of 124I, 64Cu, 86Y and 89Zr in the short-term and 44Sc, 45Ti and 90Nb later. In coming years the OPAL reactor will begin producing pharmaceutical grade 177Lu as part of the Australian government's investment in nuclear medicine.
Radiometal Labelling Research and Development
In addition to our programs developing new ligands, tracers and improved radiometal labelling procedures, Lifesciences is supporting the development of new biomolecule treatments by providing researchers access to laboratories, procedures and expertise tailored specifically for functionalising biomolecules for radiometal labelling.
Preclinical Radiometal Tracer Development
We are working to deliver novel radiometal-based diagnostic tracers to the Australian research and clinical community by accessing the pre-clinical programs of our key international partnerships at Memorial Sloan Kettering Cancer Centre and Massachusetts General Hospital. Our initial objective is to supply the antibodies, i.e. [ 89 Zr]-J591. As our supply radiometals is diversified we will expand into proteins, peptides and other biomolecules. © 2013 John Wiley & Sons, Inc.
Description
Open Access
Keywords
Positron computed tomography, Australia, ANSTO, Radiopharmaceuticals, Radioisotopes, OPAL Reactor, Nuclear medicine, Labelling, Tracer techniques
Citation
Lengkeek, N., Pellegrini, P., Oehlke, E., Fraer, B., & Greguric, I. (2013). Developing national capability for the production and use of radiometal based radiopharmaceuticals. Poster presented at the 43rd Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine (ANZSNM), 11-15 April, 2013, Perth Convention and Exhibition Centre, Perth Australia. In Internal Medicine Journal, 43 (S1), 22. doi:10.1111/imj.12133